Unknown

Dataset Information

Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer.


ABSTRACT:

Purpose

Pembrolizumab-based regimens are conditioned by the expression of PD-L1, but durable response rate is limited by innate and acquired resistance mechanisms. Here, we focus on osteopontin (OPN), an upfront biomarker of senescence, which closely associated with natural history of non-small cell lung cancer (NSCLC).

Methods

Seventy-nine patients eligible to pembrolizumab regimens-alone or in combination with chemotherapy-as first-line treatment of advanced NSCLC were enrolled. Predictive value of OPN toward iRECIST progression disease (PD) was set as first outcome. Secondary ones included performance status (ECOG) at baseline, early (first and best) responses, and overall survival (OS).

Results

High Serum OPN characterized patients with worse ECOG-PS (p = 0.015) a

SUBMITTER: Ramoni D 

PROVIDER: S-EPMC11009777 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature